Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: A systematic review and meta-analysis

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Liu, Jiali ^a   Li, Ling ^a   Li, Sheyu ^a   Jia, Pengli ^a   Deng, Ke ^a   Chen, Wenwen ^a   Sun, Xin ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLICATION; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; ODDS RATIO; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; URINARY TRACT INFECTION;

DIABETES MELLITUS, TYPE 2; HUMANS; ODDS RATIO; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; URINARY TRACT INFECTIONS;

EID: 85020394574     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-02733-w     Document Type: Article

References (36)

1. Hasan, F. M., Alsahli, M., & Gerich, J. E. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes research and clinical practice. 104, 297-322 (2014
2. Dardi, I., Kouvatsos, T., & Jabbour, S. A. SGLT2 inhibitors. Biochemical pharmacology. 101, 27-39, doi: 10.1016/j.bcp.2015.09.005 (2016
3. Zaccardi, F., et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis. Diabetes, obesity, & metabolism. 18, 783-794 (2016
4. Vasilakou, D., et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Annals of internal medicine. 159, 262-274, doi: 10.7326/0003-4819-159-4-201308200-00007 (2013
5. U.S. Food and Drug Administration. FDA approves Farxiga to treat type 2 diabetes [FDA NEWS RELEASE]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm380829.htm, (Date of access: 10 November 2016) (2014
6. U.S. Food and Drug Administration. FDA approves Invokana to treat type 2 diabetes [FDA NEWS RELEASE]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm, (Date of access: 10 November 2016) (2013
7. U.S. Food and Drug Administration. FDA approves Jardiance to treat type 2 diabetes [FDA News Release]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm407637.htm, (Date of access: 10 November 2016) (2014
8. European Medicines Agency. Forxiga (dapagliflozin): EPAR summary for the public. EMEA/H/C/002322. http://www.ema.europa. eu/docs/en-GB/document-library/EPAR---Summary-for-the-public/human/002322/WC500136025.pdf, (Date of access: 10 November 2016) (2012
9. European Medicines Agency. Invokana (canagliflozin): EPAR summary for the public. EMEA/H/C/002649. http://www.ema. europa.eu/docs/en-GB/document-library/EPAR---Summary-for-the-public/human/002649/WC500156455.pdf, (Date of access: 10 November 2016) (2013
10. European Medicines Agency. Jardiance (empagliflozin): EPAR summary for the public. EMEA/H/C/002677. http://www.ema. europa.eu/docs/en-GB/document-library/EPAR---Summary-for-the-public/human/002677/WC500168595.pdf, (Date of access: 10 November 2016) (2014
11. Markham, A., & Elkinson, S. Luseogliflozin: first global approval. Drugs. 74, 945-950, doi: 10.1007/s40265-014-0230-8 (2014
12. Poole, R. M., & Dungo, R. T. Ipragliflozin: first global approval. Drugs. 74, 611-617, doi: 10.1007/s40265-014-0204-x (2014
13. Poole, R. M., & Prossler, J. E. Tofogliflozin: first global approval. Drugs. 74, 939-944, doi: 10.1007/s40265-014-0229-1 (2014
14. Benfield, T., Jensen, J. S., & Nordestgaard, B. G. Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia. 50, 549-554, doi: 10.1007/s00125-006-0570-3 (2007
15. Geerlings, S., Fonseca, V., Castro-Diaz, D., List, J., & Parikh, S. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes research and clinical practice. 103, 373-381, doi: 10.1016/j.diabres.2013.12.052 (2014
16. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm, (Date of access: 10 November 2016) (2015
17. Kawalec, P., Mikrut, A., & Lopuch, S. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes/metabolism research and reviews. 30, 269-283, doi: 10.1002/dmrr.v30.4 (2014
18. Wu, J. H., et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. The lancet. Diabetes, & endocrinology. 4, 411-419, doi: 10.1016/S2213-8587(16)00052-8 (2016
19. Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. International journal of surgery (London, England). 8, 336-341, doi: 10.1016/j.ijsu.2010.02.007 (2010
20. ClinicalTrials.gov. Why should I register and submit results? http://www.clinicaltrials.gov/ct2/manage-recs/background, (Date of access: 10 November 2016) (2015
21. US Food and Drug Administration. Food and Drug Administration Amendments Act (FDAAA) of 2007. US Public Law 110-85 section 801. http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf, (Date of access: 10 November 2016) (2007
22. Higgins, J. P., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed.). 343, d5928-d5928, doi: 10.1136/bmj.d5928 (2011
23. Guyatt GH, Busse JW. Modification of Cochrane Tool to assess risk of bias in randomized trials. http://distillercer.com/resources/methodological-resources/, (Date of access: 10 November 2016) (2013
24. Akl, E. A., et al. Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid. Journal of clinical epidemiology. 65, 262-267, doi: 10.1016/j.jclinepi.2011.04.015 (2012
25. Higgins, J. P. T., & Green, S. The Cochrane Collaboration network http://handbook.cochrane.org, (Date of access: 10 November 2016) (2011
26. Sun, X., Briel, M., Walter, S. D., & Guyatt, G. H. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ (Clinical research ed.). 340, c117-c117, doi: 10.1136/bmj.c117 (2010
27. Guyatt, G., et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of clinical epidemiology. 64, 383-394, doi: 10.1016/j.jclinepi.2010.04.026 (2011
28. Zinman, B., et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England journal of medicine. 373, 2117-2128, doi: 10.1056/NEJMoa1504720 (2015
29. Inagaki, N., et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebocontrolled, 12-week study. Diabetes, obesity, & metabolism. 15, 1136-1145, doi: 10.1111/dom.12149 (2013
30. Seino, Y., et al. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Current medical research and opinion. 30, 1245-1255, doi: 10.1185/03007995.2014. 912983 (2014
31. Liakos, A., et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes, obesity, & metabolism. 16, 984-993, doi: 10.1111/dom.12307 (2014
32. Neal, B., et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-a randomized placebo-controlled trial. American heart journal. 166, 217-223.e211-223, doi: 10.1016/j.ahj.2013.05.007 (2013
33. AstraZeneca, B-M Squibb, The TIMI Study Group, Hadassah Medical Organization, Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58). National Library of Medicine (US), 2000. http://clinicaltrials.gov/show/NCT01730534, (Date of access: 10 November 2016) (2012
34. M Sharp, & D Corp, Pfizer. Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004). National Library of Medicine (US), 2000. http://clinicaltrials.gov/show/NCT01986881, (Date of access: 10 November 2016) (2013
35. Berhan, A., & Barker, A. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. BMC endocrine disorders. 13, 58, doi: 10.1186/1472-6823-13-58 (2013
36. Liu, X. Y., Zhang, N., Chen, R., Zhao, J. G., & Yu, P. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years. Journal of diabetes and its complications. 29, 1295-1303, doi: 10.1016/j.jdiacomp.2015.07.011 (2015